Akari Therapeutics
IPOPublic · London, United Kingdom · Founded 2012 · $14.6M raised
- Headquarters
- London
- Employees
- 1–10
- Founded
- 2012
- Business Model
- B2B
- Website
- akaritx.com
- Total Funding
- $14.6M
- Last Round
- $5.0M Venture RoundDec 2025
- Rounds
- 3
- Type
- Public
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
About
Akari Therapeutics is a clinical-stage oncology biotechnology company developing next-generation antibody-drug conjugates (ADCs) with a novel spliceosome-targeting payload (PH1). The company's lead program, AKTX-101, is advancing toward a Phase 1 first-in-human clinical trial. Akari is listed on Nasdaq (AKTX) and operates from New York and Boston.
Summary
Akari Therapeutics is a Biotech company based in London, United Kingdom, founded in 2012. It has raised $14.6M in total across 3 rounds, most recently a $5.0M Venture Round in Dec 2025.
Tech & App Stack
1 technology or app tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Dec 2025
Sign up to see all 3 events
Funding: Venture Round. Amounts, valuations, and investors where available.
Similar Companies
Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...
Clinical-stage precision medicine company developing targeted therapies for immune-mediated infla...
San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...
Clinical-stage biopharmaceutical developing precision medicines targeting novel mechanisms to tre...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/akari-therapeutics"><img src="https://indexed.vc/api/badge/company/akari-therapeutics" alt="Akari Therapeutics on Indexed.vc" width="260" height="76" /></a>